[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 513
Citations 0
Comment & Response
July 2014

Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved

Author Affiliations
  • 1Institute of Neurology, Catholic University, Rome, Italy
JAMA Neurol. 2014;71(7):924-925. doi:10.1001/jamaneurol.2014.1135

To the Editor Cohen et al1 reported the efficacy and safety results of switching from natalizumab to fingolimod in patients with multiple sclerosis in a real-practice setting in the ENIGM (Enquête Nationale sur I’Introduction du Fingolimod en Relais au Natalizumab) study. We read the article with great interest; however, we are afraid that some of the presented results may not be conclusively supported by the analyses that were performed.

First Page Preview View Large
First page PDF preview
First page PDF preview
×